Mechanisms of action: aspirin

Thromb Res Suppl. 1983:4:47-51. doi: 10.1016/0049-3848(83)90357-2.

Abstract

Aspirin, one of the oldest antiplatelet agents used for antithrombotic therapy, has been demonstrated to cause acetylation of the cyclo-oxygenase and irreversible inhibition of thromboxane synthesis for the life of the platelet. Aspirin has a similar effect upon the endothelial cyclo-oxygenase, but in contrast to that of the platelet, it is less sensitive and has the capacity to generate new cyclo-oxygenase activity if aspirin is removed from the system. Other non-steroidal anti-inflammatory agents such as ibuprofen react in a reversible manner with either the platelet or the endothelium and may actually "protect" the cyclo-oxygenase against aspirin or other agents which interact with the cyclo-oxygenase. Aspirin may act in other ways to exert an antithrombotic effect, but cause and effect relationships have not yet been demonstrated.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Arachidonic Acid
  • Arachidonic Acids / metabolism
  • Aspirin / pharmacology*
  • Blood Platelets / metabolism
  • Cyclooxygenase Inhibitors
  • Endothelium / metabolism
  • Humans
  • Ibuprofen / pharmacology
  • In Vitro Techniques
  • Indomethacin / pharmacology
  • Salicylates / pharmacology
  • Salicylic Acid
  • Thromboxanes / metabolism

Substances

  • Arachidonic Acids
  • Cyclooxygenase Inhibitors
  • Salicylates
  • Thromboxanes
  • Arachidonic Acid
  • Salicylic Acid
  • Aspirin
  • Ibuprofen
  • Indomethacin